Arcus Biosciences
RCUS
185 hedge funds and large institutions have $811M invested in Arcus Biosciences in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 84 increasing their positions, 51 reducing their positions, and 26 closing their positions.
1,644% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $1.52M
65% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 51
6% more capital invested
Capital invested by funds: $763M → $811M (+$48.2M)
2.33% more ownership
Funds ownership: 91.85% → 94.18% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 186 → 185 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$26.5M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$9.63M |
| 3 |
Morgan Stanley
New York
|
+$5.83M |
| 4 |
BlackRock
New York
|
+$5.05M |
| 5 |
Jane Street
New York
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$9.63M |
| 3 |
DC
Decheng Capital
Menlo Park,
California
|
-$5.54M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$5.26M |
| 5 |
Millennium Management
New York
|
-$3.54M |
RCUS Hedge Fund Activity: Q2 2025 in Review
185 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2025, worth a combined $811M — up 6.3% from $763M a quarter earlier.
Fund positioning in RCUS was balanced in Q2 2025: 26 funds opened new positions, 26 closed out, 84 added to existing stakes and 51 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $26.5M. The largest seller was Fidelity Investments, cutting an estimated $16.1M.
- 185 institutional investors held Arcus Biosciences (RCUS) as of Q2 2025, down from 186 in Q1 2025.
- Funds reported $811M of Arcus Biosciences stock for Q2 2025, up 6.3% quarter-over-quarter.
- 26 funds opened new Arcus Biosciences positions in Q2 2025 and 26 closed out, a net change of 0 holders.
- The largest Arcus Biosciences buyer in Q2 2025 was Point72 Asset Management, an estimated $26.5M added.
- The largest Arcus Biosciences seller in Q2 2025 was Fidelity Investments, an estimated $16.1M sold.
Based on aggregated 13F filings for Q2 2025.